Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clarithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ipratropium bromide anhydrous -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ipratropium bromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluvoxamine maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin -

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-17823 sodium laurilsulfate titanium dioxide water - canesoral fluconazole capsule, given orally, is indicated for vaginal candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg; clotrimazole 10 mg/g - combination - 150mg & 10mg/g - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-17823 sodium laurilsulfate titanium dioxide water active: clotrimazole 10 mg/g excipient: benzyl alcohol cetostearyl alcohol cetyl palmitate octyldodecanol polysorbate 60 purified water sorbitan stearate - vaginal candidiasis. cream can be used for relief of external itching/irritation and the management of candida vulvovaginitis or infection of the peri-anal area.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration